The targeted drug delivery market is experiencing significant growth driven by advancements in nanotechnology, biotechnology, and precision medicine. Nanoparticles, liposomes, and dendrimers are being increasingly used to deliver drugs directly to the target site, improving therapeutic efficacy and reducing side effects. One major development is the use of stimuli-responsive systems, where drugs are released in response to specific environmental factors, such as pH or temperature changes at the target site.
In addition, the use of biologically compatible carriers, such as antibodies and aptamers, allows for highly selective drug targeting. These carriers bind to specific receptors on the surface of cells, ensuring that the drug is delivered to the intended tissue or organ.
The growth in this market is also fueled by increasing incidences of chronic diseases, such as cancer and cardiovascular diseases, where targeted therapies offer promising outcomes. Regulatory support and growing investments in research and development are further accelerating innovation, with the market expected to grow significantly over the next decade.
